Back to Stakeholders
Categories

2 domains / 4 areas / 2 specializations

Research, Drug Development & Manufacturing
Academic & Non-Profit ResearchUniversities and Colleges with Dedicated Psychedelic Research Groups
Research, Drug Development & Manufacturing
Media, Education & Engagement
Educational Platforms & ResourcesOnline Resources
Media, Education & Engagement

Stanford University

Data updated

United States
10 Trials3 Papers

At the Stanford School of Medicine, researchers from the Rodriguez Lab and the Heifets Lab have united under the banner of the Stanford Psychedelic Science Group. Their primary clinical focus is to investigate compounds including ketamine, psilocybin, and MDMA as potential treatments for debilitating disorders such as obsessive-compulsive disorder (OCD), treatment-resistant depression, and post-traumatic stress disorder (PTSD).

IntroductoryHybridFreeAcademic programmeContinuing educationCurious publicAspiring practitionersLicensed cliniciansResearchersOther

Blossom’s read

Stanford’s psychedelic offering sits closer to an academic, research-led public education hub than a commercial training school. The strongest signal is its free, university-based Introduction to Psychedelic Medicine course and a wider programme of talks and mentorship around sanctioned research, which makes it particularly credible for clinicians, trainees, and researchers who want rigorous orientation rather than a practitioner credential. It is well-connected to Stanford Medicine’s psychedelic research groups, with a lineage that appears rooted in psychiatry, anaesthesiology, and translational neuroscience rather than facilitation or retreat culture.

Who Stanford University is for

Best suited to mental health professionals, trainees, students, and researchers who want a science-first overview of psychedelic medicine. It also looks relevant for people exploring the field academically, rather than those seeking a stand-alone certification to practise.

Prerequisites

No formal prerequisites were stated for the SPSG education page. The PSYC 215B syllabus indicates the course is framed around sanctioned research and does not endorse illicit use, but it does not state licensure or entry conditions in the sources reviewed.

Accreditation & recognition

No psychedelic-specific certification, licensure, or formal credential was identified. Stanford Medicine does run accredited continuing education more broadly through its CME office, which is jointly accredited by ACCME, ACPE, and ANCC, but the reviewed psychedelic pages did not clearly state that PSYC 215B itself carries CME/CE credit.

Cost

Stanford Psychedelic Science Group states its mission is to offer free, high quality education. I did not find published tuition or fee information for PSYC 215B in the reviewed sources, so I cannot confirm whether enrolment is free or whether standard Stanford course fees apply.

What you walk away with

Learners appear to walk away with a structured academic understanding of psychedelic medicine, including history, clinical evidence, safety, ethics, trial design, and current research directions. The sources do not indicate a formal credential, only educational exposure, networking, and mentorship within Stanford’s research community.

Academic Research

3 papers

Published Papers

3

Trial Involvement

10

Distinct Focus Topics

0

Latest Publication

Apr 8, 2026

Similar course providers

Reference points selected from shared training modalities, learner audience, level, delivery format, pricing, and location.

University of Pennsylvania
  • Strong match: 2 shared modalities
  • Strong match: 5 shared learner audiences
  • Also shares: introductory level
  • Also shares: hybrid delivery
Florida International University
  • Strong match: 2 shared modalities
  • Strong match: 4 shared learner audiences
  • Also shares: introductory level
  • Also shares: hybrid delivery
Southwestern College
  • Strong match: 2 shared modalities
  • Strong match: 3 shared learner audiences
  • Also shares: introductory level
  • Also shares: hybrid delivery
Free University Amsterdam
  • Strong match: 2 shared modalities
  • Strong match: 4 shared learner audiences
  • Also shares: introductory level
  • Also shares: hybrid delivery

Quick Facts

Type
academic
HQ
United States
Website
Visit

Sponsored Trials

9
Not yet recruiting

Outcomes Registry After Ketamine Infusions for Chronic Pain: A Longitudinal Evaluation

Start Date
Compounds
Ketamine
Not yet recruitingII

Anesthesia-Masked Psilocybin Therapy for Major Depression

Start Date
Compounds
Psilocybin, Placebo
Active not recruitingIV

Propofol-Enhanced Assessment of Ketamine for Chronic Pain and Depression (PEAK)

Start Date
Compounds
Ketamine, Placebo
RecruitingII

Examining Mu Opioid Mechanisms of Ketamine’s Rapid Effects in OCD (MKET2) (MKET2)

Start Date
Compounds
Ketamine, Placebo
CompletedNA

Pre-post Evaluation of the Safety and Efficacy of Ibogaine-Magnesium Therapy in Veterans With Repeated Blast Exposure

Start Date
CompletedNA

Stanford Reward Circuits of the Brain Study – MDMA

Start Date
Compounds
MDMA, Placebo
CompletedIII

Opiate Suicide Study in Patients With Major Depression

Start Date
Compounds
Ketamine, Placebo
CompletedIV

Intraoperative Ketamine Versus Saline in Depressed Patients Undergoing Anesthesia for Non-cardiac Surgery

Start Date
Compounds
Ketamine, Placebo
CompletedI

Double-Blind Trial of Ketamine Therapy Plus or Minus Naltrexone in Treatment Resistant Depression (TRD)

Start Date
Compounds
Ketamine, Placebo

Collaborated Trials

1
CompletedII

Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)

Start Date
Compounds
Ketamine, Placebo

Research Papers

3
Paywallindividual

General Anesthesia and Discrete Components of Ketamine Neurophysiology

This cohort study (n=52) examined how general anaesthesia changes ketamine’s brain activity patterns in healthy volunteers, surgical patients and people with depression. Ketamine given during general anaesthesia kept its beta-gamma effects but lost the usual theta increase, suggesting these neurophysiological components can be separated.

Published
Journal
JAMA Psychiatry
Authors
Deverett, B., Li, D., Lii, T. R., Vlisides, P. E., Tarnal, V., Forsyth, A., Sumner, R., Sikka, P., Schatzberg, A. F., Muthukumaraswamy, S., Mashour, G. A., Heifets, B. D.
Open AccessindividualPrimary

Increased cortical thickness and decreased brain age among special operations veterans with blast TBI after a magnesium-ibogaine protocol

This secondary analysis of an observational study (n=30) - named MISTIC - of Special Operations Forces veterans with blast-related traumatic brain injury, examined ibogaine given with magnesium and found increased cortical thickness, larger subcortical volumes and a lower estimated brain age one month later. The authors note that the MRI changes could reflect neuroplastic effects, although the scans may also be influenced by non-structural factors.

Published
Journal
iScience
Authors
Geoly, A. D., Coetzee, J. P., Buchanan, D. M., Struckmann, W., Kim, B., Sridhar, M., Azeez, A., Lissemore, J. I., Cherian, K., Faerman, A., Keynan, J. N., Singal, P., Shanbour, A., Bandeira, I. D., Kratter, I. H., Adamson, M. M., Saggar, M., Rolle, C., Williams, N. R.
Open AccessindividualLong-term follow-up

Magnesium-ibogaine therapy in veterans with traumatic brain injuries

This observational study (n=30) evaluates ibogaine (up to 980mg/70kg) in combination with magnesium (1-2 hours before and 12 hours later) in male Special Operations Forces veterans with predominantly mild traumatic brain injury (mTBI). The study assessed changes in disability, PTSD, depression, and anxiety immediately and one month after treatment using various scales. Results show significant improvements in functioning and psychological symptoms with no serious adverse events.

Published
Journal
Nature Medicine
Authors
Cherian, K. N., Keynan, J. N., Anker, L., Faerman, A., Brown, R. E., Shamma, A., Keynan, O., Coetzee, J. P., Batail, J. M., Phillips, A., Bassa, N. J., Sahlem, G. L., Inzunza, J., Millar, T., Dickinson, J., Rol, C. E., Keller, J., Adamson, M., Kratter, I. H., Williams, N. R.